3NE4 image
Deposition Date 2010-06-08
Release Date 2011-12-14
Last Version Date 2023-09-06
Entry Detail
PDB ID:
3NE4
Title:
1.8 Angstrom structure of intact native wild-type alpha-1-antitrypsin
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.81 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
C 1 2 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Alpha-1-antitrypsin
Gene (Uniprot):SERPINA1
Chain IDs:A
Chain Length:424
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Therapeutic target-site variability in [alpha]1-antitrypsin characterized at high resolution
Acta Crystallogr.,Sect.F 67 1492 1497 (2011)
PMID: 22139150 DOI: 10.1107/S1744309111040267

Abstact

The intrinsic propensity of α(1)-antitrypsin to undergo conformational transitions from its metastable native state to hyperstable forms provides a motive force for its antiprotease function. However, aberrant conformational change can also occur via an intermolecular linkage that results in polymerization. This has both loss-of-function and gain-of-function effects that lead to deficiency of the protein in human circulation, emphysema and hepatic cirrhosis. One of the most promising therapeutic strategies being developed to treat this disease targets small molecules to an allosteric site in the α(1)-antitrypsin molecule. Partial filling of this site impedes polymerization without abolishing function. Drug development can be improved by optimizing data on the structure and dynamics of this site. A new 1.8 Å resolution structure of α(1)-antitrypsin demonstrates structural variability within this site, with associated fluctuations in its upper and lower entrance grooves and ligand-binding characteristics around the innermost stable enclosed hydrophobic recess. These data will allow a broader selection of chemotypes and derivatives to be tested in silico and in vitro when screening and developing compounds to modulate conformational change to block the pathological mechanism while preserving function.

Legend

Protein

Chemical

Disease

Primary Citation of related structures